Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Reviewer: Ryan P. Smith, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 4 de julio del 2004
Authors: Horig H, et al.
Source: Cancer Immunol Immunother 49, 2000, pg 504
This study does represent the first use of a novel approach to cancer vaccination. The administration of a co-stimulatory molecule appears to be key in animal and laboratory studies. Therefore, this study tested a vaccination with the costimulatory molecule B7.1 with an anti-CEA vaccine. As this was a phase I trial, most importantly, there were no major toxicities and no evidence of autoimmunity. The concern over the generation of an autoimmune response was warranted, as CEA is expressed on much of the intestinal epithelium. The efficacy of the vaccine, however, is in question. Granted, this was a phase I trial, not designed to investigate efficacy per se, but the authors indicate that the responses seen were encouraging. This is true from the standpoint that all of these patients had been treated many times before, likely with resultant dulled immune systems. They also had metastatic disease, likely unresponsive to conventional intervention. From that respect, the response in three patients is excellent. However, the definition they used for stable disease allowed the tumor to progress up to 25%. In addition, a T-cell immune response was seen in only 4 patients. Though this is an indirect measure of the efficacy of the vaccine, it is still an indication that the vaccine may require further refinement. Regardless, in the complex field of immunology and cancer vaccines, the fact that this study used a tumor specific antigen laden vaccine with the novel addition of the costimulatory molecule makes it an important step in the development of an effective cancer vaccine.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults